Although CBF-AML has a favorable overall prognosis, most reports indicate that co-occurrence of KIT mutations confer an adverse prognosis in AML with both inv(16) and t(8;21), and a higher incidence of relapse in AML with inv(16) (41–44). This evidence concerns the gene KIT and acute myeloid leukemia.